RNA5SP217

Across TCGA pan-cancer cohorts, RNA5SP217 RNA differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of RNA5SP217’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where RNA5SP217 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RNA5SP217 is over-expressed in tumor, although a few such as BRCA show the opposite, repressed pattern.

KIRC, STAD, and KIRP are the cancer types where RNA5SP217 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RNA5SP217 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	All	+0.539	<.001	6	view →
STAD	All	III,IV	+0.997	.006	4	view →
KIRP	Male	II,III,IV	+0.528	.016	4	view →
BRCA	All	All	−0.374	.004	4	view →
HNSC	Female	All	+0.506	.021	2	view →
LIHC	Female	All	+0.278	.011	2	view →
LUSC	Male	III,IV	+0.977	.031	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

RNA5SP217–KIRC

Open the KIRC breakdown →